Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”).
The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price is set, which was €1.76, in accordance with the 12th resolution of the extraordinary general meeting of shareholders of the Company held on May 20, 2020. The Reserved Offering is expected to close on or about September 22, 2020.
The Reserved Offering was conducted by Jefferies International Limited (“Jefferies”), as Sole Global Coordinator and Joint Bookrunner, and Bryan, Garnier & Co and Kempen & Co, as Joint Bookrunners (together with Jefferies, the "Placing Agents"). Chardan is acting as Lead Manager. Namsen Capital is acting as equity capital markets advisor.
The Company intends to use the net proceeds from the Reserved Offering to develop its current gene therapy programs (OTOF and USHER), potentially broaden its gene therapy pipeline, support its pharmacology, clinical studies for the phase 3 development of SENS-401 and for working capital as well as general corporate purposes.
Following the issuance of the New Shares, the Company's total share capital will be 7,679,905.20 euros equal to 76,799,052 shares, each with a par value of €0.10. Based on its forecasted expenses, the cash at December 31, 2019 and the net proceeds from the present offering the Company believes it will be able to fund its operations into end of Q3 2022.
On an illustrative basis, a shareholder holding 1% of the Company's share capital before the Reserved Offering and who did not participate in the Reserved Offering will now hold 0.8% of the Company's share capital after the Reserved Offering. To the Company's knowledge, the shareholding structure, on a non-diluted base, before and after the Reserved Offering breaks down as follows:
Number of shares before the Reserved Offering (1)
% of the share capital before the Reserved Offering
% of voting rights before the Reserved Offering
Number of shares after the Reserved Offering (1)
% of share capital after the Reserved Offering
% of voting rights after the Reserved Offering
Inserm Transfert Inititiative
Management, employees and directors
Invus Public Equities LP
(1)To the Company’s knowledge and based on the last analysis from August 2020.
Invus Public Equities LP, and Sofinnova Partners subscribed to the capital increase, for a total amount of €16.2 million, which represents 9,529,552 new shares or 52% of the total number of new shares issued as part of this capital increase.
The New Shares will be admitted to trading on the non-regulated market of Euronext Growth in Paris upon their settlement and delivery, which is expected to occur on or about September 22, 2020. They will be listed under the same code as the Company’s existing ordinary shares (ISIN FR0012596468), carry dividend rights as from their issue date and be immediately fungible in all respects with the Company’s existing shares.
The Reserved Offering was not subject to a prospectus to be approved by the French financial markets authority (Autorité des marchés financiers - the “AMF”).
In connection with the Reserved Offering, the Company has entered into a lock-up agreement restricting the issuance of additional ordinary shares for a period ending 90 days after the execution of the placement and underwriting agreement entered into between the Company and the Placing Agents (the "Placement Agreement”), subject to customary exceptions. The Company’s management, Board members and shareholders represented on the Board of Directors, who hold ordinary shares of the Company, are also subject to a lock-up for a period of 90 days after the execution of the Placement Agreement, subject to customary exceptions.
Pursuant to the placement and underwriting agreement entered between the Company and the Placing Agents, the settlement and delivery of the part of the Reserved Offering placed with investors outside of the U.S. is guaranteed by the Placing Agents.
The Company draws the public’s attention to the risk factors related to the Company and its activities presented in section I.3 of the Rapport financier annuel for the year ended December 31, 2019, which is available free of charge on the website of the Company (www.sensorion-pharma.com).
In addition, investors are invited to consider the following risks: (i) the market price for the Company's shares may fluctuate and fall below the subscription price of the shares issued pursuant to the Reserved Offering, (ii) the volatility and liquidity of the Company's shares may fluctuate significantly, (iii) sales of the Company’s shares may occur on the market and have a negative impact on the market price of the shares, and (iv) the Company’s shareholders could undergo a potentially material dilution resulting from any future capital increases that are needed to finance the Company.
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders. Its clinical-stage portfolio includes one Phase 2 product: SENS- 401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases enabling it to select the best targets and modalities for drug candidates. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. In the second half of 2019, Sensorion launched two preclinical gene therapy programs aiming at correcting hereditary monogenic forms of deafness including Usher Type 1 and deafness caused by a mutation of the gene encoding for Otoferlin. The Company is uniquely placed, through its platforms and pipeline of potential therapeutics, to make a lasting positive impact on hundreds of thousands of people with inner ear related disorders, a significant global unmet medical need.
This press release does not constitute an offer to sell or the solicitation of an offer to buy ordinary shares of the Company, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the “Prospectus Regulation”).
In France, the Reserved Offering described above took place solely as a placement to a category of institutional investors, in accordance with Article L. 225-138 of the “Code de commerce” and applicable regulations.
With respect to Member States of the European Economic Area (including France), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release which would require the publication of a prospectus (pursuant to article 3 of the Prospectus Regulation) in any Member State.
This press release and the information it contains is not an offer to sell, nor the solicitation of an offer to subscribe for or buy, New Shares in the United States or any other jurisdiction where restrictions may apply including notably Canada, Australia or Japan. Securities may not be offered or sold in the United States absent registration under the Securities Act or an exemption from registration thereunder. Sensorion does not intend to register the New Shares under the Securities Act or conduct a public offering of the New Shares in France, the United States, or in any other jurisdiction.
This communication is being distributed only to, and is directed only at (a) persons outside the United Kingdom, (b) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), and (c) high net worth entities, and other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this communication or any of its contents.
Solely for the purposes of each manufacturer’s product approval process, the target market assessment in respect of the New Shares has led to the conclusion in relation to the type of clients criteria only that: (i) the type of clients to whom the New Shares are targeted is eligible counterparties, professional clients and retail clients, each as defined in Directive 2014/65/EU, as amended (“MiFID II”); and (ii) all channels for distribution of the New Shares to eligible counterparties, professional clients and retail clients are appropriate. Any person subsequently offering, selling or recommending the New Shares (a “distributor”) should take into consideration the manufacturers’ type of clients assessment; however, a distributor subject to MiFID II is responsible for undertaking its own target market assessment in respect of the New Shares (by either adopting or refining the manufacturers’ type of clients assessment) and determining appropriate distribution channels.For the avoidance of doubt, even if the target market includes retail clients, the Placing Agents have decided they will only procure investors for the New Shares who meet the criteria of eligible counterparties and professional clients.
This distribution of this press release may be subject to legal or regulatory restrictions in certain jurisdictions. Any person who comes into possession of this press release must inform him or herself of and comply with any such restrictions.
This press release has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of any of the Placing Agents or any of their parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person’s respective directors, officers, employees, agents, affiliates or advisers, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this press release and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this press release is subject to verification, correction, completion and change without notice.
The Placing Agents are acting exclusively for the Company and no one else in connection with the Reserved Offering and will not regard any other person (whether or not a recipient of this press release) as their client in relation to the Reserved Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their client nor for providing advice in relation to the proposed Reserved Offering. Jefferies is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
+33 6 27 74 74 49
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle21.10.2020 11:00:00 CEST | Press release
Bacardi, the world’s largest family-owned spirits company, has made a giant leap forward in the fight against climate change and plastic pollution today, as it unveils plans to put the world’s most sustainable spirits bottle on shelf by 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005281/en/ Bacardi First in Fight Against Plastic Pollution With 100% Biodegradable Spirits Bottle (Photo: Business Wire) The new 100% biodegradable bottle will replace 80 Million plastic bottles – 3,000 tons of plastic – currently produced by Bacardi across its portfolio of brands every year. This revolutionary move by Bacardi is possible thanks to its close collaboration with Danimer Scientific, a leading developer and manufacturer of biodegradable products. Petroleum-based plastics used by Bacardi today will be replaced by Danimer Scientific’s Nodax™ PHA, a biopolymer which derives from the natural oils of plant seeds such as palm,
1 GWh of Daily Solar Production Is Optimized and Monitored by Tigo Solutions Globally21.10.2020 11:00:00 CEST | Press release
This summer, Tigo Energy Inc.’s fleet of monitored module-level power electronics (MLPE) crossed a major milestone – more than 1 GWh of daily solar production. The fleet includes tens of thousands of communicating systems that span all seven continents on sites ranging from single kilowatt residential scale to multi-megawatt utility scale PV installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005322/en/ Tigo's fleet of monitored PV systems spans all 7 continents and generates more than one gigawatt-hour of energy per day. (Graphic: Business Wire) “This is a significant milestone that’s the result of years of hard work by our team and our amazing network of partners that literally span the globe,” said Zvi Alon, Chairman and CEO of Tigo Energy. The daily production is tracked using Tigo’s cloud monitoring platform, which has the most granular data visibility available in the market. End customers and installat
Lionbridge International Wins 3M EMEA Supplier of the Year Award21.10.2020 10:00:00 CEST | Press release
Lionbridge International, a global leader in localisation and AI training data solutions, was honored with the 2019 3M Supplier of the Year Award in recognition of the company’s contribution to improving 3M’s competitiveness. This year,3M recognized 12 suppliers, among thousands in its global supply base, for world class performance in providing products and/or services. These suppliers were identified and rated based on strategic spend, contract compliance, actions taken to improve 3M’s relevance and overall supplier performance (quality, delivery, responsiveness, cost, and technology roadmaps). “We are truly delighted to receive this prestigious award as it recognizes our commitment and dedication to support 3M by providing agile communications which resonate locally and amplify their global brand,” said Corinne Saunders, EMEA Managing Director, Lionbridge. “Our partnership has evolved over many years to the global engagement we have today and this award showcases the trust, shared v
Ooredoo Algeria Pushes to 10Gbps its Wireless Mobile Backhaul with SIAE MICROELETTRONICA21.10.2020 09:00:00 CEST | Press release
Ooredoo a leader in mobile services, together with SIAE MICROELETTRONICA, a leading supplier of microwave and millimetre wave radio for mobile backhauling, established another record in the country pushing mobile backhaul capacity to 10Gbps. Ooredoo Algeria is unceasingly working to maximise its mobile backhaul capacity, establishing one of the most technologically advance transport infrastructure in the region. This latest achievement is part of the ongoing e-band and multiband backhaul upgrade program to a multi-gigabit infrastructure. The 10Gbps link has been achieved by upgrading an existing link operating at the maximum channel bandwidth allowed in the country of 1GHz, to a 2+0 configuration over a single antenna, effectively doubling the link capacity. “Investing in new technologies is fundamental in building resilient networks capable of withstanding unexpected situation” says Abdelkrim Melab, Head of Transmission Engineering at Ooredoo Algeria, adding “this has been possible th
Vertical Group Holding: BNP Paribas Leadership MUST Come to Malta for Questioning in Case Alleging Anti-semitism and Corruption, Court Rules, Following Extended Legal Fight Over Their Attendance21.10.2020 09:00:00 CEST | Press release
BNP Paribas’ CEO and Chairman have been ordered to appear before a Maltese court, where they face questions about the French bank’s alleged involvement with a highly controversial deal in Malta, and about serious alleged ethical, legal and professional violations at the bank, Vertical Group Holding announces today. Jean-Laurent Bonnafé and Jean Lemierre, two of France’s highest-profile executives, will be pressed to give evidence as witnesses in court concerning their roles in an alleged plot by BNP Paribas to discredit a financier of British-Israeli background who had criticized the bank over its admitted involvement in multiple criminal activities, including money-laundering for pariah regimes. Jacob Agam, alongside Malta-based Vertical Group, the international private equity group he chairs, is bringing a civil lawsuit against both men and BNP itself for what he alleges was the bank’s deliberate and unlawful destruction of the business’s assets. BNP and the executives dispute the cl
MYbank Shortens Payment Cycles for Small and Micro Businesses in the Lead up to This Year’s 11.11 Global Shopping Festival21.10.2020 06:38:00 CEST | Press release
MYbank, a leading online private commercial bank in China with a focus on serving small and micro businesses, today announced a program to provide RMB 400 billion of collateral-free credit to businesses in need as they gear up for this year’s 11.11 Global Shopping Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020006336/en/ Leveraging Ant Group's technologies, MYbank has pioneered the “310 model” that enables SMEs to apply for collateral-free business loans that take less than three minutes to apply for on a mobile phone, less than one second to approve, and requires zero human intervention. (Photo: Business Wire) As part of the dedicated program, MYbank is offering a total of RMB 200 billion in short-term loans to help small and micro business owners overcome the economic impact of the COVID-19 pandemic. This enables business owners, particularly smaller vendors with more immediate capital needs, to receive pay